NCT04939090
Breast Cancer Type: HER2+, Triple Negative
Hormone Mutations:
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic leptomeningeal disease or known brain metastases; Patients with a hormone-sensitive tumor
https://ClinicalTrials.gov/show/NCT04939090